GlaxoSmithKline's New Drug Challenges HIV Treatment Orthodoxy

GlaxoSmithKline ’s ViiV Healthcare announced positive phase-three trial results for its new HIV drug in a dual-drug regimen, supporting the company’s audacious bet that it can shift the treatment orthodoxy away from three-drug combinations.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news
More News: Pharmaceuticals